Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape
American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)
DOI: 10.1200/edbk-26-520506 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Maeve A Hennessy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 overexpression. Historically, treatment options for TNBC have been limited, because of the absence of actionable targets. The addition of immune checkpoint inhibitors to chemotherapy improved outcomes for a subset of patients with metastatic PD-L1–positive disease; however, a critical need for more effective therapies remains. Antibody-drug conjugates (ADCs) have been a promising advance in the management of advanced TNBC and are reshaping the landscape as they move earlier into the treatment algorithm. A greater understanding of the molecular heterogeneity of TNBC has enabled the pursuit of more targeted and personalized therapeutic strategies. Despite this, TNBC continues to have the least favorable outcomes compared with other breast cancer subtypes. This review highlights current evidence and future challenges in advanced TNBC, including optimizing therapeutic sequencing and the ongoing need for predictive biomarkers and novel agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.
- Internal Medicine Residency Program, Department of Medicine, University of Chicago, Chicago, IL.
- Division of Medical Oncology, Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN.
- Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
- Department of Medical Oncology, UT Southwestern Medical Center, Dallas, TX.
Zitieren
APA
Hennessy, M. A., Terman, E., Idossa, D., LeVee, A., Leon-Ferre, R. A., McArthur, H., & Nanda, R. (2026). Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-520506
Vancouver
Hennessy MA, Terman E, Idossa D, LeVee A, Leon-Ferre RA, McArthur H, et al. Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-520506
BibTeX
@article{Hennessy2026,
author = {Hennessy, Maeve A and Terman, Elizabeth and Idossa, Damé and LeVee, Alexis and Leon-Ferre, Roberto A and McArthur, Heather and Nanda, Rita},
title = {Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape},
journal = {American Society of Clinical Oncology Educational Book},
year = {2026},
volume = {46},
number = {3},
doi = {10.1200/edbk-26-520506}
}
EUVIMED